Northern Trust Corp Fate Therapeutics Inc Transaction History

Northern Trust Corp

  • $572 Billion
  • Q1 2024

A detailed history of Northern Trust Corp transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Northern Trust Corp holds 716,052 shares of FATE stock, worth $2.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
716,052
Previous 708,589 1.05%
Holding current value
$2.35 Million
Previous $2.65 Million 98.3%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$3.54 - $8.35 $26,419 - $62,316
7,463 Added 1.05%
716,052 $5.26 Million
Q4 2023

Feb 13, 2024
SELL
$1.65 - $3.94 $890,377 - $2.13 Million
-539,623 Reduced 43.23%
708,589 $2.65 Million
Q3 2023

Nov 13, 2023
SELL
$2.02 - $5.04 $8,582 - $21,414
-4,249 Reduced 0.34%
1,248,212 $2.65 Million
Q2 2023

Aug 11, 2023
BUY
$4.76 - $6.59 $2.22 Million - $3.08 Million
467,171 Added 59.49%
1,252,461 $5.96 Million
Q1 2023

May 15, 2023
BUY
$4.24 - $11.12 $92,660 - $243,016
21,854 Added 2.86%
785,290 $4.48 Million
Q4 2022

Feb 13, 2023
SELL
$9.86 - $23.83 $42,043 - $101,611
-4,264 Reduced 0.56%
763,436 $7.7 Million
Q3 2022

Nov 14, 2022
SELL
$21.04 - $36.06 $172,675 - $295,944
-8,207 Reduced 1.06%
767,700 $17.2 Million
Q2 2022

Aug 12, 2022
SELL
$17.78 - $42.39 $69,786 - $166,380
-3,925 Reduced 0.5%
775,907 $19.2 Million
Q1 2022

May 13, 2022
SELL
$29.67 - $60.28 $957,599 - $1.95 Million
-32,275 Reduced 3.97%
779,832 $30.2 Million
Q4 2021

Feb 08, 2022
SELL
$47.84 - $64.34 $540,113 - $726,398
-11,290 Reduced 1.37%
812,107 $47.5 Million
Q3 2021

Nov 15, 2021
SELL
$59.27 - $95.73 $3.63 Million - $5.87 Million
-61,283 Reduced 6.93%
823,397 $48.8 Million
Q2 2021

Aug 13, 2021
BUY
$67.25 - $92.52 $172,025 - $236,666
2,558 Added 0.29%
884,680 $76.8 Million
Q1 2021

May 12, 2021
SELL
$72.16 - $117.4 $811,511 - $1.32 Million
-11,246 Reduced 1.26%
882,122 $72.7 Million
Q4 2020

Feb 11, 2021
SELL
$38.09 - $100.95 $923,225 - $2.45 Million
-24,238 Reduced 2.64%
893,368 $81.2 Million
Q3 2020

Nov 16, 2020
BUY
$30.41 - $40.5 $1.18 Million - $1.58 Million
38,911 Added 4.43%
917,606 $36.7 Million
Q2 2020

Aug 14, 2020
BUY
$20.21 - $35.23 $1.6 Million - $2.78 Million
78,975 Added 9.88%
878,695 $30.1 Million
Q1 2020

May 14, 2020
BUY
$17.28 - $31.88 $157,075 - $289,789
9,090 Added 1.15%
799,720 $17.8 Million
Q4 2019

Feb 14, 2020
BUY
$13.39 - $20.73 $1.26 Million - $1.96 Million
94,310 Added 13.54%
790,630 $15.5 Million
Q3 2019

Nov 13, 2019
SELL
$15.47 - $22.5 $872,136 - $1.27 Million
-56,376 Reduced 7.49%
696,320 $10.8 Million
Q2 2019

Aug 13, 2019
BUY
$15.61 - $20.44 $51,887 - $67,942
3,324 Added 0.44%
752,696 $15.3 Million
Q1 2019

May 13, 2019
BUY
$13.15 - $18.71 $182,259 - $259,320
13,860 Added 1.88%
749,372 $13.2 Million
Q4 2018

Feb 12, 2019
BUY
$11.48 - $16.98 $1.27 Million - $1.88 Million
110,936 Added 17.76%
735,512 $9.44 Million
Q3 2018

Nov 14, 2018
BUY
$8.75 - $16.29 $492,660 - $917,192
56,304 Added 9.91%
624,576 $10.2 Million
Q2 2018

Sep 18, 2018
SELL
$9.16 - $13.48 $23,916 - $35,196
-2,611 Reduced 0.46%
568,272 $6.44 Million
Q2 2018

Aug 14, 2018
BUY
$9.16 - $13.48 $677,510 - $997,034
73,964 Added 14.88%
570,883 $6.47 Million
Q1 2018

May 09, 2018
BUY
$6.3 - $13.77 $683,568 - $1.49 Million
108,503 Added 27.93%
496,919 $4.85 Million
Q4 2017

Feb 14, 2018
SELL
$3.94 - $6.64 $17,863 - $30,105
-4,534 Reduced 1.15%
388,416 $2.37 Million
Q3 2017

Nov 13, 2017
BUY
$2.6 - $4.31 $1.02 Million - $1.69 Million
392,950
392,950 $1.56 Million

Others Institutions Holding FATE

# of Institutions
178
Shares Held
124M
Call Options Held
222K
Put Options Held
48.6K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $318M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email